CGP 37849(Cat No.:M116301)is a competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, acting specifically at the glutamate recognition site. By blocking NMDA receptor activation, it inhibits excitatory neurotransmission and protects against excitotoxicity, a key mechanism in neuronal injury. CGP 37849 has been widely studied in models of epilepsy, stroke, ischemia, and neurodegenerative diseases such as Alzheimer’s, where NMDA overactivation contributes to pathology. Its ability to reduce seizure activity and neurotoxicity makes it a valuable pharmacological tool for investigating glutamatergic signaling and potential therapeutic strategies targeting excitatory neurotransmission.